Antibody-dependent enhancement (ADE) of infection may cause severe illness in patients suffering a secondary infection by a heterologous dengue virus (DENV) serotype. During ADE of infection, cross-reactive non- or poorly-neutralizing antibodies form infectious virus-Ab complexes with the newly infecting serotype and enhance virus infection by binding to the Fcγ receptors (FcγR) on FcγR-bearing cells. In this study, we determined that molecular determinants of DENV2 envelope protein critical for virus entry during non-ADE infection are also required for ADE infection mediated by FcγRIIA, and binding of virus-Ab complexes with FcγRIIA alone is not sufficient for ADE of infection. The FcγRIIA mainly plays an auxiliary role in concentrating the virus-Ab complex to the cell surface, and other primary cellular receptors are required for virus entry. Understanding the viral entry pathway in ADE of DENV infection will greatly facilitate rational designs of anti-viral therapeutics against severe dengue disease associated with ADE.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4583201 | PMC |
| http://dx.doi.org/10.1016/j.virol.2014.03.031 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Signal detection and analysis of adverse events associated with Genvoya based the FAERS database.
Front Pharmacol
December 2024
Department of Pharmacy, West China Second University Hospital, Sichuan University, Chengdu, Sichuan, China.
Objective: This study aims to evaluate and understand the safety profile of Genvoya by mining and analyzing adverse drug event (ADE, adverse drug event) reports from the FDA Adverse Event Reporting System (FAERS, FDA Adverse Event Reporting System) database, thus providing valuable reference information for individuals infected with HIV.
Methods: Data were obtained from the FAERS database, covering the period from the first quarter of 2015 to the fourth quarter of 2023, focusing on reports where Genvoya was the primary suspected drug. Data import and extraction were conducted using MySQL 8.
The SARS-CoV-2 antibody-dependent enhancement façade.
Microbes Infect
December 2024
Department of Health Sciences, Brock University, St. Catharines, Ontario, L2S 3A1, Canada. Electronic address:
Antibody-dependent enhancement (ADE) is an immunological paradox whereby sensitization following a primary viral infection results in the subsequent enhancement of a similar secondary infection. This idiosyncratic immune response has been established in dengue virus infections, driven by four antigenically related serotypes co-circulating in endemic regions. Several coronaviruses exhibit antibody-mediated mechanisms of viral entry, which has led to speculation of an ADE capacity for SARS-CoV-2, though in vivo and epidemiological evidence do not currently support this phenomenon.
View Article and Find Full Text PDFAdverse Drug Events in Ambulatory Care: A Cross-Sectional Study.
Drug Saf
December 2024
Division of General Internal Medicine and Primary Care, Brigham and Women's Hospital, Boston, MA, USA.
Article Synopsis
Antibiotic allergy de-labeling in the intensive care unit: The prospective ADE-ICU study.
J Crit Care
February 2025
Department of Anaesthesiology, Intensive Care and Pain Medicine, St. James's Hospital, Dublin, Ireland; Trinity College Dublin, Dublin, Ireland. Electronic address:
Purpose: Critically ill patients in the intensive care unit (ICU) are frequently prescribed antibiotics, with many reporting an antibiotic allergy label, predominantly to penicillin. Mislabeling contributes to suboptimal antibiotic use, increasing multidrug-resistant organisms and Clostridium difficile infections, and increased hospital length of stay. This prospective study implemented an antibiotic allergy assessment and testing program in the ICU, independently of clinical immunology/allergy services.
View Article and Find Full Text PDFAn engineered Japanese encephalitis virus mRNA-lipid nanoparticle immunization induces protective immunity in mice.
Front Microbiol
November 2024
School of Basic Medical Sciences, Health Science Center, Ningbo University, Ningbo, China.
Article Synopsis
- The study investigates the effects of antibodies from Japanese encephalitis virus (JEV) and Zika virus (ZIKV) infections on each other, focusing on a phenomenon called antibody-dependent enhancement (ADE), where the presence of one virus's antibodies can worsen the infection by the other virus.* -
- Researchers created modified vaccine candidates using recombinant adenoviruses and mRNA to examine their effectiveness in generating immune responses against JEV and the potential for cross-reactivity with ZIKV, finding that certain modifications lead to a reduced risk of ADE.* -
- Immunization with the modified vaccine candidates resulted in lower cross-reactive antibody levels and effective T cell responses, indicating that these vaccines could protect against JEV while minimizing the dangers
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!